AI-powered growth surges as Haier Biomedical scales from product coverage to premium brand leadership, building a global life science tools and intelligent productivity platform

QINGDAO, China, April 30, 2026 /CNW/ -- Haier Biomedical (688139.SH), a global leader in life sciences and medical solutions, has officially published its 2025 annual report, posting full‑year revenue of 2.33 billion yuan (USD 340.77 million) with overseas revenue growing 17.9% year-on-year to 840 million yuan (USD 122.85 million), accounting for 36% of total revenue, a record high. Despite a complex global trade environment, Haier Biomedical delivered double‑digit growth across all international business sectors.

After a decade of global expansion, Haier Biomedical has evolved from "product export" to "brand globalization." In 2025, overseas revenue delivered strong compound growth, with double-digit increases across Europe, Asia-Pacific, the Americas, and Africa, including 26.0% growth in Asia-Pacific and 16.0% in Europe.

For the first time, the company unveiled its future strategic blueprint centered on "growth leapfrogging," driven by three pathways: market leap, industry leap, and model leap. The vision is to build a world-leading integrated life science tools and intelligent productivity platform.

Haier Biomedical continued to optimize its revenue structure in 2025, with new market sectors and overseas operations emerging as core engines ...